Skip to main content

Advertisement

SpringerLink
Log in

Chronic migraine: comorbidities, risk factors, and rehabilitation

  • Symposium: Chronicisation of Headaches. Natural Evolution, Drugs Dependence and Rehabilitation
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Migraine is a serious illness with a spontaneous clinical evolution into a chronic form. In some episodic migraines, increase of crises frequency modifies the headache pattern in the chronic form, defined as chronic migraine (CM), with headache frequency of 15 days/month. One-year prevalence of CM includes around 2–4% of the general population. Migraine progression from episodic to chronic form is realized through a period of time involving several months or years, during which an increase of attack frequency occurs. Migraine shows a wide spectrum of comorbidities, including cardiocerebral, vascular, psychiatric, metabolic, neurologic as well as other pathologies. The single/multiple presence of such comorbidities represents a fixed factor in the process of chronicization into CM. Risk factors including medication overuse headache (MOH), obesity, and lifestyle cooperate in the evolution process to CM. MOH is the most severe complication of CM, and similarly to CM its appearance is gradual. Both CM and MOH show particular genetic background able to favor the appearance of chronicity and abuse. Rehabilitation consists of drug withdrawal procedures, re-prophylaxis through administration of innovative drugs, such as OnabotulinumtoxinA and/or topiramate, to avoid relapsing attacks, and behavioral strategies to minimize the role of risk factors. The initial relief step for drug abusers always relies in drug withdrawal. The feasible diagnostic setting for a CM tailored treatment based on the application of pharmacogenomics will allow us to predetermine the efficacy of single old and new drugs by avoiding abuse due to non-responsivity of the acute drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746

    Article  CAS  PubMed  Google Scholar 

  2. Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review of the Eurolight project. J Headache Pain. doi:10.1007/s10194-010-0217-0

  3. Silberstein S, Olesen J, Bousser MG et al (2005) The international classification of headache disorders, 2nd edn (ICHD-II). Revised of criteria for 8.2 medication-overuse headache. Cephalalgia 25:460–465

    Google Scholar 

  4. Allena M, Katsarava Z, Nappi G, the COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 10:71–76

    Article  PubMed  Google Scholar 

  5. Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol 9:391–401

    Article  PubMed  Google Scholar 

  6. Rossi P, Jensen R, Nappi G, Allena M, the COMOESTAS Consortium (2009) A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 10:407–417

    Article  PubMed  Google Scholar 

  7. Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276

    Article  PubMed  Google Scholar 

  8. Pompili M, Serafini G, Di Cosimo D, Innamorati M, Lester D, Forte D, Girardi N, De Filippis S, Tatarelli R, Martelletti P (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 6:81–91

    Article  PubMed  Google Scholar 

  9. Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10:283–290

    Article  PubMed  Google Scholar 

  10. Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63–65

    Article  PubMed  Google Scholar 

  11. Kurth T (2007) Migraine and ischaemic vascular events. Cephalalgia 27:967–975

    Article  Google Scholar 

  12. Tzourio C, Tehindrazanarivelo A, Iglesias S et al (1995) Case–control study of migraine and risk of ischaemic stroke in young women. BMJ 310:830–833

    CAS  PubMed  Google Scholar 

  13. Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case–control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Br Med J 318:13–18

    CAS  Google Scholar 

  14. Kurth T, Gaziano JM, Cook NR et al (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291

    Article  CAS  PubMed  Google Scholar 

  15. Stang PE, Carson AP, Rose KM et al (2005) Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64:1573–1577

    Article  CAS  PubMed  Google Scholar 

  16. Kruit MC, van Buchem MA, Hofman PAM et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427–434

    Article  CAS  PubMed  Google Scholar 

  17. Spector JJ, Kahn SR, Jones SR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123:612–634

    Article  PubMed  Google Scholar 

  18. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339:b3914

    Article  PubMed  Google Scholar 

  19. Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease. A population-based study. Neurology 74:628–635

    Article  CAS  PubMed  Google Scholar 

  20. Schwedt TJ (2009) The migraine association with cardiac anomalies, cardiovascular disease and stroke. Neurol Clin 27:513–523

    Article  PubMed  Google Scholar 

  21. Dalla Volta G, Guindani M, Zavarise P et al (2005) Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain 6:328–330

    Article  PubMed  Google Scholar 

  22. Ferrarini G, Malferrari G, Zucco R et al (2005) High prevalence of patent foramen ovale in migraine with aura. J Headache Pain 6:71–76

    Article  PubMed  Google Scholar 

  23. Tembl J, Lago A, Sevilla T et al (2007) Migraine, patent foramen ovale and migraine triggers. J Headache Pain 8:7–12

    Article  PubMed  Google Scholar 

  24. Jesurum JT, Fuller CJ, Velez CA et al (2007) Migraineurs with patent foramen ovale have larger right-to left shunt despite similar atrial septal characteristics. J Headache Pain 8:209–216

    Article  PubMed  Google Scholar 

  25. Wilmshurst PT, Nightingale S, Walsh KP et al (2005) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke for haemodynamic reasons. Lancet 356:1648–1651

    Article  Google Scholar 

  26. Azarbal B, Tobis J, Suh W et al (2005) Association of interatrial shunts and migraine headaches. J Am Coll Cardiol 45:489–492

    Article  PubMed  Google Scholar 

  27. Thenganatt J, Schneiderman J, Hyland RH et al (2006) Migraines linked to intrapulmonary right-to-left shunt. Headache 46:439–443

    Article  PubMed  Google Scholar 

  28. Litman GI, Friedman HM (1978) Migraine and the mitral valve prolapse syndrome. Am Heart J 96:610–614

    Article  CAS  PubMed  Google Scholar 

  29. Spence JD, Wong DG, Melendez LJ et al (1984) Increased prevalence of mitral valve prolapse in patients with migraine. Can Med Assoc J 131:1457–1460

    CAS  PubMed  Google Scholar 

  30. Carerj S, Narbone MC, Zito C et al (2003) Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 43:725–728

    Article  CAS  PubMed  Google Scholar 

  31. Truong T, Slavin L, Kashani R et al (2008) Prevalence of migraine headaches in patients with congenital heart disease. Am J Cardiol 101:396–400

    Article  PubMed  Google Scholar 

  32. Innamorati M, Pompili M, De Filippis S, Gentili F, Erbuto D, Lester D, Tamburello A, Iacorossi G, Cuomo I, Dominici G, Tatarelli R, Martelletti P (2009) The validation of the Italian perceived disability scale (IPDS) in chronic daily headache sufferers. J Headache Pain 10:21–26

    Article  PubMed  Google Scholar 

  33. Oedegaard KJ, Angst J, Neckelmann D, Fasmer OB (2005) Migraine aura without headache compared to migraine with aura in patients with affective disorders. J Headache Pain 6:378–386

    Article  PubMed  Google Scholar 

  34. Franchini L, Bongiorno F, Dotoli D, Rainero I, Pinessi L, Smeraldi E (2004) Migraine headache and mood disorders: a descriptive study in an out-patient psychiatric population. J Affect Disord 81:157–160

    Article  PubMed  Google Scholar 

  35. Cuvellier JC, Carvalho S, Mars A, Auvin S (2009) Study on management of pediatric migraine by general practitioners in northern France. J Headache Pain 10:167–175

    Article  PubMed  Google Scholar 

  36. Cuvellier JC, Donnet A, Guégan-Massardier E, Nachit-Ouinekin F, Parain D, Vallée L (2009) Treatment of primary headache in children: a multicenter hospital-based study in France. J Headache Pain 10:447–453

    Article  PubMed  Google Scholar 

  37. Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P (2010) Patient outcome in migraine prophylaxis: the role of psycopharmacological agents. Patient Relat Outcome Meas 1:1–12

    Google Scholar 

  38. Villani V, Bruti G, Mostradini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R (2005) Migraine in the Emergency Department: a psychometric study of a migraine “repeaters” sample. J Headache Pain 6:301–303

    Article  PubMed  Google Scholar 

  39. De Filippis S, Erbuto D, Gentili F, Innamorati M, Lester D, Tatarelli R, Martelletti P, Pompili M (2008) Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain 9:349–357

    Article  PubMed  Google Scholar 

  40. Vargas BB, Dodick DW (2009) The face of chronic migraine: epidemiology, demographics and treatment strategies. Neurol Clin 27:467–479

    Article  PubMed  Google Scholar 

  41. Buse DC, Marcia FT, Rupnow FT, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422–435

    Article  PubMed  Google Scholar 

  42. Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how we can prevent relapse? Int Emerg Med. doi:10.1007/s11739-010-0410-9

  43. Trucco M, Meineri P, Ruiz L, on behalf of the “gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee” (Neurological Hospital Interregional Group for the Study of Headaches) (2010) Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 6:334–337

    Article  Google Scholar 

  44. Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. doi:10.1007/s10194-010-0221-4

  45. Rossi P, Faroni JV, Nappi G (2010) Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. doi:10.1111/j.1468-1331.2010.03157.x

  46. Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opin Neurol 23:254–258

    Article  CAS  PubMed  Google Scholar 

  47. Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 7:407–412

    Article  CAS  PubMed  Google Scholar 

  48. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Trial. (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803

    Article  CAS  PubMed  Google Scholar 

  49. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, on behalf of the PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814

    Article  CAS  PubMed  Google Scholar 

  50. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF, on behalf of the PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Pooled a results from the double-blind, randomized, placebo-controlled phases of the PREEMPT Clinical Program. Headache 50:921–936

    Article  PubMed  Google Scholar 

  51. Ruiz L, Ferrandi D (2009) Topiramate in migraine progression. J Headache Pain 10:419–422

    Article  CAS  PubMed  Google Scholar 

  52. Stovner LJ, Tronvik E, Hagen K (2009) New drugs for migraine. J Headache Pain 10:395–406

    Article  CAS  PubMed  Google Scholar 

  53. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Int Emerg Med 4:367–373

    Article  Google Scholar 

  54. Mathew NT, Farhan AJ (2009) A double-blind comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466–1478

    Article  PubMed  Google Scholar 

  55. Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P (2010) Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 11:151–156

    Article  CAS  PubMed  Google Scholar 

  56. Di Lorenzo C, Di Lorenzo G, Sances G et al (2009) Drug consumption in medication overuse headache is influenced by brain derived neurotrophic factor Val66Met polymorphism. J Headache Pain 10:349–355

    Article  PubMed  Google Scholar 

  57. Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9:1267–1269

    Article  PubMed  Google Scholar 

  58. Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. doi:10.1007/s10194-010-0241-0

Download references

Acknowledgments

This review is part of the educational programme lead by Lifting The Burden – The WHO Global Campaign against Headache. In the preparation of this manuscript AN collected and analyzed the references. PM and LD discussed the review’s profile. AN and PM prepared and critically discussed the manuscript. All authors approved the final draft.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Regional Referral Headache Centre and Internal Medicine, Department of Clinical and Molecular Sciences, II School of Medicine, Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1035, 00189, Rome, Italy

    Andrea Negro, Lidia D’Alonzo & Paolo Martelletti

Authors
  1. Andrea Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lidia D’Alonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Martelletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Martelletti.

Additional information

P. Martelletti is Chairman, Lifting The Burden, The WHO Global Campaign against Headache (http://www.who.int/mental_health/neurology/headache/en/).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Negro, A., D’Alonzo, L. & Martelletti, P. Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5 (Suppl 1), 13–19 (2010). https://doi.org/10.1007/s11739-010-0457-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-010-0457-7

Keywords

Search

Navigation